Literature DB >> 27648133

Condition medium of HepG-2 cells induces the transdifferentiation of human umbilical cord mesenchymal stem cells into cancerous mesenchymal stem cells.

Juan Yang1, Yinglei Miao2, Yefei Chang3, Fan Zhang1, Yubo Wang1, Sheng Zheng1.   

Abstract

This study aimed to investigate the transdifferentiation of human umbilical cord mesenchymal stem cells (hUCMSCs) into cancer-associated mesenchymal stem cells (CA-MSCs) after incubation with condition medium (CM) from liver cancer HepG-2 cells, and the biobehaviors (proliferation and migration) of these CA-MSCs were further evaluated. The supernatant of HepG-2 cells was collected and mixed with equal volume of low glucose DMEM. The resultant medium was used to treat hUCMSCs for 48 h. The expression of CA-MSCs related proteins and miR-221 was detected in cells. The supernatant of induced hUCMSCs was mixed with equal volume of high glucose DMEM, and the resultant medium was used treat HepG-2 cells for 48 h and the proliferation and migration of HepG-2 cells were evaluated. Moreover, HepG-2 cells were co-cultured with hUCMSCs and then the proliferation and migration of HepG-2 cells were assessed. After incubation with the supernatant from HepG-2 cells, hUCMSCs showed significantly elevated expression of vimentin, fibroblast activation protein (FAP) and miR-221. The supernatant of induced hUCMSCs was able to significantly increase the proliferation and migration of HepG-2 cells. Following co-culture, the proliferation and migration of HepG-2 cells increased dramatically. These findings suggest that the supernatant of HepG-2 cells is able to induce the phenotype of CA-MSCs and the supernatant of CA-MSCs may promote the proliferation and migration of HepG-2 cells. These findings provide experimental evidence for the cellular remodeling in tumor microenvironment and the safety of clinical use of hUCMSCs.

Entities:  

Keywords:  Stem cells; cell migration; hepatocellular carcinoma; transdifferentiation; umbilical cord mesenchymal stem cells

Year:  2016        PMID: 27648133      PMCID: PMC5009395     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  24 in total

Review 1.  Immunosuppressive properties of mesenchymal stem cells: advances and applications.

Authors:  M P De Miguel; S Fuentes-Julián; A Blázquez-Martínez; C Y Pascual; M A Aller; J Arias; F Arnalich-Montiel
Journal:  Curr Mol Med       Date:  2012-06       Impact factor: 2.222

Review 2.  The tumour microenvironment as a target for chemoprevention.

Authors:  Adriana Albini; Michael B Sporn
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

3.  Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow.

Authors:  Dolores Baksh; Raphael Yao; Rocky S Tuan
Journal:  Stem Cells       Date:  2007-03-01       Impact factor: 6.277

4.  MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis.

Authors:  Benjamin G Cuiffo; Antoine Campagne; George W Bell; Antonio Lembo; Francesca Orso; Evan C Lien; Manoj K Bhasin; Monica Raimo; Summer E Hanson; Andriy Marusyk; Dorraya El-Ashry; Peiman Hematti; Kornelia Polyak; Fatima Mechta-Grigoriou; Odette Mariani; Stefano Volinia; Anne Vincent-Salomon; Daniela Taverna; Antoine E Karnoub
Journal:  Cell Stem Cell       Date:  2014-10-16       Impact factor: 24.633

Review 5.  Bone marrow-derived mesenchymal stem cells and the tumor microenvironment.

Authors:  Scott A Bergfeld; Yves A DeClerck
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 6.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

7.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

Review 8.  Chemopreventive Effects of Alpha Lipoic Acid on Obesity-Related Cancers.

Authors:  Hyun-Seuk Moon
Journal:  Ann Nutr Metab       Date:  2016-02-02       Impact factor: 3.374

9.  Mesenchymal stromal cells promote tumor progression in fibrosarcoma and gastric cancer cells.

Authors:  Byunghoo Song; Bokyung Kim; Se-Ha Choi; Kyo Young Song; Yang-Guk Chung; Youn-Soo Lee; Gyeongsin Park
Journal:  Korean J Pathol       Date:  2014-06-26

Review 10.  Polysplenia Syndrome With Splenic and Skeletal Muscle Metastases From Thyroid Carcinoma Evaluated by FDG PET/CT: Case Report and Literature Review: A Care-Compliant Article.

Authors:  Zu-Gui Li; Zhi-Chun Lin; Hai-Yu Mu
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

View more
  5 in total

Review 1.  Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.

Authors:  Hoda Elkhenany; Ahmed Shekshek; Mohamed Abdel-Daim; Nagwa El-Badri
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  Suppression of tumor cell proliferation and migration by human umbilical cord mesenchymal stem cells: A possible role for apoptosis and Wnt signaling.

Authors:  Yin Yuan; Chang Zhou; Xuan Chen; Changli Tao; Huiqing Cheng; Xin Lu
Journal:  Oncol Lett       Date:  2018-03-28       Impact factor: 2.967

Review 3.  TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment.

Authors:  Zhenghou Zhang; Xiangyu Zhou; Jinshuai Guo; Fusheng Zhang; Yiping Qian; Guang Wang; Meiqi Duan; Yutian Wang; Haiying Zhao; Zhi Yang; Zunpeng Liu; Xiaofeng Jiang
Journal:  J Transl Med       Date:  2022-07-16       Impact factor: 8.440

Review 4.  Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential.

Authors:  Zhengjun Lin; Yanlin Wu; Yiting Xu; Guoqing Li; Zhihong Li; Tang Liu
Journal:  Mol Cancer       Date:  2022-09-13       Impact factor: 41.444

Review 5.  Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.

Authors:  Ellen Puré; Rachel Blomberg
Journal:  Oncogene       Date:  2018-05-03       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.